Viramune en es it fr

Viramune Brand names, Viramune Analogs

Viramune Brand Names Mixture

  • No information avaliable

Viramune Chemical_Formula


Viramune RX_link

Viramune fda sheet

Viramune FDA

Viramune msds (material safety sheet)

Viramune MSDS

Viramune Synthesis Reference

Hargrave, Karl D., et al.; J.Med.Chem.; 34; 7;2231-2241(1991).

Viramune Molecular Weight

266.298 g/mol

Viramune Melting Point


Viramune H2O Solubility

0.7046 mg/L

Viramune State


Viramune LogP


Viramune Dosage Forms

Tablets; Oral suspension

Viramune Indication

For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.

Viramune Pharmacology

Nevirapine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by nevirapine. Nevirapine is, in general, only prescribed after the immune system has declined and infections have become evident. It is always taken with at least one other HIV medication such as Retrovir or Videx. The virus can develop resistance to nevirapine if the drug is taken alone, although even if used properly, nevirapine is effective for only a limited time.

Viramune Absorption

90% (absolute bioavailability 93 ± 9%)

Viramune side effects and Toxicity

Symptoms of overdose include edema, erythema nodosum, fatigue, fever, headache, insomnia, nausea, pulmonaryinfiltrates, rash, vertigo, vomiting, and weight decrease.

Viramune Patient Information

Viramune Organisms Affected

Human immunodeficiency virus